Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

nt to the end of the quarter, Omeros received a payment of $12.5 million from CCIC pursuant to the terms of the settlement agreement. Omeros also received $4.9 million in net proceeds from the sale of 373,700 shares of its common stock, sold at an average price of $13.29 per share, pursuant to the company's at-the-market equity facility in October 2013.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for the second half of 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-l
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (PRWEB) July 23, 2014 StemGenex® ... therapy in the US aimed at improving the lives ... newest clinical study for Parkinson’s disease. StemGenex believes ... stem cell therapy are paramount when providing care to ... study makes stem cell therapy accessible to the millions ...
(Date:7/23/2014)... 23, 2014 DuPont Pioneer announced today ... vice president of Agricultural Biotechnology (ABT), effective July 21, ... served most recently as president, chief executive officer and ... leadership in the seed and crop protection industry to ... E. Schickler , president of DuPont Pioneer. “I am ...
(Date:7/23/2014)... 23, 2014 regulated information -- UCB today announced ... pipeline with positive topline results from the latest ... was designed to evaluate the efficacy and safety ... without titration) compared to placebo, as adjunctive treatment ... not fully controlled despite treatment with one or ...
(Date:7/23/2014)... Sciences, Inc. (OTCQB: GBLX), a medical cannabis research and development ... marijuana dispensary locations in Las Vegas, Nevada ... Clark County, Nevada dispensary for which the company ... GrowBLOX Sciences, CEO Craig Ellins stated, "We ... in the City of Las Vegas . ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3
... is Superior to Placebo, Similar Efficacy to ... a Day, and Less Daytime Drowsiness, ... (Nasdaq:,CEPH) announced the pooled analysis of two ... (cyclobenzaprine,hydrochloride extended-release capsules), a new once-daily extended-release,skeletal ...
... Quantitative Research ... Worldwide, NEW YORK, ... of those fielded in the US and abroad -- were,conducted online last ... report, released today, indicates that Internet-based market,research -- once the orphan of ...
... Inc. (Nasdaq: ONXX ) today announced that it ... and full year 2007,financial results and provide a business ... Time (2:00 p.m. Pacific Time). Financial results,for the fourth ... released,earlier that day., Interested parties may access a ...
Cached Biology Technology:Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 2Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 3Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 4Technology Transforms Market Research in Pharmaceutical Industry 2Technology Transforms Market Research in Pharmaceutical Industry 3Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 2
(Date:7/23/2014)... Children who have been abused or neglected early ... emotional and physical health problems. In a new ... way genes are activated, which has implications for ... a particular child,s individual characteristics and genetics interacted ... understand how health problems emerge. In the new ...
(Date:7/23/2014)... are highly sensitive to temperature and to protect developing ... narrow range. Recently published research led by Philip T. ... and Sciences, is the first to show that worker ... similar to how humans and other mammals cool themselves ... study shows how workers effectively dissipate the heat absorbed ...
(Date:7/23/2014)... super strength, but it also holds the promise of ... ability to convert sunlight into a clean, efficient alternative ... international group using spinach to study the proteins involved ... sun,s energy into carbohydrates used to power cellular processes. ... most efficient system ever built, capable of converting the ...
Breaking Biology News(10 mins):Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3How honey bees stay cool 2Spinach could lead to alternative energy more powerful than Popeye 2
... South Florida researchers from the University of Miami,s Cooperative ... National Oceanic and Atmospheric Administration,s Atlantic Oceanographic and Meteorological ... was, as predicted, being pulled into the Loop Current ... The University of Miami,s 96-foot catamaran the RV/F.G. ...
... Vancouver, BC - The economically important, environmentally sensitive ... having its genome fully sequenced, thanks to an ... from Canada, Chile and Norway., Genome BC partnered ... Research Council, Norwegian Fishery and Aquaculture Industry Research ...
... the new comic book, Small Changes Big Results from the ... University. Their quest is to create a healthier lifestyle for ... moms are like real-life moms in Latino farm workers, families, ... children, says Jill Kilanowski, assistant professor at the Frances Payne ...
Cached Biology News:Scientists locate oil plume extending toward Dry Tortugas 2Scientists locate oil plume extending toward Dry Tortugas 3Comic book moms are nutrition heroes to guide migrant family health 2
... its Best: DASGIPs Process Control integrates ... & comprehensive documentation for cultivation processes. ... as pH, dissolved oxygen, temperature and ... online. Profiles, e.g. constant or scheduled ...
... blotting is a commonly used technique for ... samples are electrophoresed on SDS-PAGE and transferred ... nylon, where they are probed with specific ... allow reuse of Southern and Northern blots, ...
... Basic Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... proteomic and general life science research applications. ... use of all dyes in the UV ...
... Introducing our Regulatory Edition of Molecular ... imaging systems for life science research and ... supports compliance with U.S. Food and Drug ... Part 11 Electronic Records; Electronic Signatures [21 ...
Biology Products: